New Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Guideline for the Management of Axial Spondyloarthritis and Canadian Rheumatology Association Position Statements on PDE5 inhibitors for the treatment of severe Raynaud’s Phenomenon, Biologic Access and National Pharmacare. Plus updated CRA living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs.

New! Choosing Wisely Canada’s Climate Conscious Recommendations. Earlier this Spring, the CRA and several other national clinician societies and organizations, developed climate-conscious recommendations for Choosing Wisely Canada. These recommendations offer practical ways to stop or reduce routine practices that harm the environment without compromising patient care.

Abstract Submission and CRA Award nominations are open! CRA abstract submission deadline is October 4, 2024. CRA Distinguished, Master and Practice Reflection award nominations due October 14, 2024.